This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Birbari, A. E. Articles by Mukaddam-Daher, S. Search for Related Content PubMed PubMed Citation Articles by Birbari, A. E. Articles by Mukaddam-Daher, S. Social Bookmarking                         What's this?

Treatment of Hypertension in the Elderly with Captopril

Division of Nephrology-Hypertension and Hariri Hypertension-Vascular Research Laboratory, American University Medical Center, Beirut, Lebanon

Majida Dauk

Division of Nephrology-Hypertension and Hariri Hypertension-Vascular Research Laboratory, American University Medical Center, Beirut, Lebanon

Suhayla Mukaddam-Daher

Division of Nephrology-Hypertension and Hariri Hypertension-Vascular Research Laboratory, American University Medical Center, Beirut, Lebanon

Fifteen elderly hypertensives aged fifty-nine to seventy-four years received captopril either as a monotherapy (group I, n=7) or as an addition to other antihypertensive drugs (group II, n=8) for twelve to fourteen months. Both the mean supine and erect blood pressure fell from 173.3 ± 3.4/93.3 ± 6.6 to 143.3±3.4/78.3±1.7 and from 166.7+8.6/98.3+4.4 to 146.7±12.0/85.0±2.9 mm Hg, respectively, in group I, and from 165.6±10.5/104.9±4.4 to 128.8±4.7/84.1±1.7 and from 154.0±10.1/107.8±3.3 to 126.3±6.0/88.8±1.2 mm Hg, respectively, in group II. There was a slight but insignificant reduction in pulse rate and body weight. Side effects were minimal. All patients experienced a sense of well-being. There was no impairment of renal function in most patients and no reduction in serum K. This study suggests that, in elderly hypertensives, captopril reduces blood pressure safely and effectively without impairing perfusion to the brain, heart, and kidneys and without causing edema or hypokalemia.

Angiology, Vol. 38, No. 5, 363-367 (1987)
DOI: 10.1177/000331978703800503


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?